Fig. 2: Clinical and functional outcomes of FMT in de novo PD patients. | Signal Transduction and Targeted Therapy

Fig. 2: Clinical and functional outcomes of FMT in de novo PD patients.

From: Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson’s disease: a randomized phase 2 trial

Fig. 2: Clinical and functional outcomes of FMT in de novo PD patients.

a UPDRS III (motor examination). b UPDRS II (motor experiences of daily living). c UPDRS I (nonmotor experiences of daily living). d Constipation Scoring System (CSS). e Patient Assessment of Constipation-Quality of Life (PAC-QoL), normalized to a 0–4 scale (raw score/28). f Gastrointestinal Symptom Rating Scale (GSRS). g SCOPA-AUT (autonomic symptoms). h Mini-Mental State Examination (MMSE). i Montreal Cognitive Assessment (MoCA). j 39-item Parkinson’s Disease Questionnaire (PDQ-39). Data are presented as the mean ± standard deviation; n = 33 per group. aFMT, autologous fecal microbiota transplantation; dFMT, donor fecal microbiota transplantation; w, week. Between-group differences were assessed at baseline and at 11, 23, and 35 weeks. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page